Therefore, HER2 alone or the HER2/HER3 signalling pathway could be effective targets to modulate or reverse drug resistance of T-ICs in luminal subtypes of BC, resulting in suppression of reoccurrence or metastasis of BC. This evidence concerns the gene ERBB3 and breast cancer.